Overall, we suggest that these mechanisms can have an impact on treatment not only of prion diseases but also for application to other neurodegenerative diseases that involve toxic interaction with the PrPC central domain or benefit from its increased α-processing. This evidence concerns the gene PRNP and neurodegenerative disease.